![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ID1 |
Gene summary for ID1 |
![]() |
Gene information | Species | Human | Gene symbol | ID1 | Gene ID | 3397 |
Gene name | inhibitor of DNA binding 1, HLH protein | |
Gene Alias | ID | |
Cytomap | 20q11.21 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P41134 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3397 | ID1 | CA_HPV_1 | Human | Cervix | CC | 7.97e-12 | -3.48e-01 | 0.0264 |
3397 | ID1 | Tumor | Human | Cervix | CC | 1.21e-76 | 1.23e+00 | 0.1241 |
3397 | ID1 | sample1 | Human | Cervix | CC | 1.90e-04 | 5.41e-01 | 0.0959 |
3397 | ID1 | sample3 | Human | Cervix | CC | 5.41e-99 | 1.28e+00 | 0.1387 |
3397 | ID1 | H2 | Human | Cervix | HSIL_HPV | 8.78e-08 | 4.73e-01 | 0.0632 |
3397 | ID1 | L1 | Human | Cervix | CC | 1.70e-10 | 5.05e-01 | 0.0802 |
3397 | ID1 | T1 | Human | Cervix | CC | 3.61e-12 | 6.09e-01 | 0.0918 |
3397 | ID1 | T2 | Human | Cervix | CC | 7.60e-04 | 6.39e-01 | 0.0709 |
3397 | ID1 | T3 | Human | Cervix | CC | 6.95e-95 | 1.28e+00 | 0.1389 |
3397 | ID1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.07e-17 | 5.75e-01 | 0.0155 |
3397 | ID1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.19e-24 | 1.02e+00 | -0.1808 |
3397 | ID1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.83e-11 | 9.25e-01 | 0.0216 |
3397 | ID1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.23e-34 | 1.62e+00 | -0.0811 |
3397 | ID1 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.31e-17 | 8.67e-01 | -0.1088 |
3397 | ID1 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.33e-27 | 9.99e-01 | -0.1954 |
3397 | ID1 | HTA11_411_2000001011 | Human | Colorectum | SER | 7.45e-08 | 1.35e+00 | -0.2602 |
3397 | ID1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.36e-06 | 1.12e+00 | -0.2196 |
3397 | ID1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.22e-33 | 1.41e+00 | -0.1207 |
3397 | ID1 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.39e-14 | 9.42e-01 | -0.1526 |
3397 | ID1 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.52e-54 | 1.61e+00 | -0.1464 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007136417 | Oral cavity | LP | cellular response to epidermal growth factor stimulus | 24/4623 | 45/18723 | 3.44e-05 | 5.18e-04 | 24 |
GO:001839312 | Oral cavity | LP | internal peptidyl-lysine acetylation | 62/4623 | 158/18723 | 3.52e-05 | 5.26e-04 | 62 |
GO:001657312 | Oral cavity | LP | histone acetylation | 60/4623 | 152/18723 | 3.80e-05 | 5.61e-04 | 60 |
GO:001657014 | Oral cavity | LP | histone modification | 152/4623 | 463/18723 | 4.04e-05 | 5.90e-04 | 152 |
GO:0032970110 | Oral cavity | LP | regulation of actin filament-based process | 133/4623 | 397/18723 | 4.21e-05 | 6.09e-04 | 133 |
GO:190165317 | Oral cavity | LP | cellular response to peptide | 122/4623 | 359/18723 | 4.22e-05 | 6.10e-04 | 122 |
GO:005149519 | Oral cavity | LP | positive regulation of cytoskeleton organization | 82/4623 | 226/18723 | 6.26e-05 | 8.46e-04 | 82 |
GO:0032956110 | Oral cavity | LP | regulation of actin cytoskeleton organization | 120/4623 | 358/18723 | 9.47e-05 | 1.18e-03 | 120 |
GO:000635413 | Oral cavity | LP | DNA-templated transcription, elongation | 39/4623 | 91/18723 | 1.08e-04 | 1.31e-03 | 39 |
GO:0007015110 | Oral cavity | LP | actin filament organization | 143/4623 | 442/18723 | 1.44e-04 | 1.65e-03 | 143 |
GO:003052013 | Oral cavity | LP | intracellular estrogen receptor signaling pathway | 26/4623 | 54/18723 | 1.57e-04 | 1.78e-03 | 26 |
GO:000636813 | Oral cavity | LP | transcription elongation from RNA polymerase II promoter | 31/4623 | 69/18723 | 1.92e-04 | 2.11e-03 | 31 |
GO:004345714 | Oral cavity | LP | regulation of cellular respiration | 24/4623 | 49/18723 | 2.00e-04 | 2.18e-03 | 24 |
GO:004346717 | Oral cavity | LP | regulation of generation of precursor metabolites and energy | 50/4623 | 130/18723 | 3.37e-04 | 3.37e-03 | 50 |
GO:007138319 | Oral cavity | LP | cellular response to steroid hormone stimulus | 71/4623 | 204/18723 | 7.42e-04 | 6.62e-03 | 71 |
GO:0051101110 | Oral cavity | LP | regulation of DNA binding | 45/4623 | 118/18723 | 8.04e-04 | 7.06e-03 | 45 |
GO:0110053110 | Oral cavity | LP | regulation of actin filament organization | 92/4623 | 278/18723 | 9.25e-04 | 7.85e-03 | 92 |
GO:003105613 | Oral cavity | LP | regulation of histone modification | 55/4623 | 152/18723 | 1.01e-03 | 8.48e-03 | 55 |
GO:001082314 | Oral cavity | LP | negative regulation of mitochondrion organization | 22/4623 | 49/18723 | 1.59e-03 | 1.22e-02 | 22 |
GO:007050715 | Oral cavity | LP | regulation of microtubule cytoskeleton organization | 53/4623 | 148/18723 | 1.60e-03 | 1.23e-02 | 53 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa043908 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0439013 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa040151 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa040152 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
hsa04350 | Colorectum | SER | TGF-beta signaling pathway | 31/1580 | 108/8465 | 7.00e-03 | 3.77e-02 | 2.74e-02 | 31 |
hsa040153 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
hsa043501 | Colorectum | SER | TGF-beta signaling pathway | 31/1580 | 108/8465 | 7.00e-03 | 3.77e-02 | 2.74e-02 | 31 |
hsa040154 | Colorectum | MSS | Rap1 signaling pathway | 66/1875 | 210/8465 | 1.03e-03 | 5.94e-03 | 3.64e-03 | 66 |
hsa04390 | Colorectum | MSS | Hippo signaling pathway | 48/1875 | 157/8465 | 8.32e-03 | 3.10e-02 | 1.90e-02 | 48 |
hsa040155 | Colorectum | MSS | Rap1 signaling pathway | 66/1875 | 210/8465 | 1.03e-03 | 5.94e-03 | 3.64e-03 | 66 |
hsa043901 | Colorectum | MSS | Hippo signaling pathway | 48/1875 | 157/8465 | 8.32e-03 | 3.10e-02 | 1.90e-02 | 48 |
hsa040156 | Colorectum | FAP | Rap1 signaling pathway | 53/1404 | 210/8465 | 7.93e-04 | 5.14e-03 | 3.13e-03 | 53 |
hsa043902 | Colorectum | FAP | Hippo signaling pathway | 41/1404 | 157/8465 | 1.49e-03 | 7.91e-03 | 4.81e-03 | 41 |
hsa040157 | Colorectum | FAP | Rap1 signaling pathway | 53/1404 | 210/8465 | 7.93e-04 | 5.14e-03 | 3.13e-03 | 53 |
hsa043903 | Colorectum | FAP | Hippo signaling pathway | 41/1404 | 157/8465 | 1.49e-03 | 7.91e-03 | 4.81e-03 | 41 |
hsa0401514 | Endometrium | AEH | Rap1 signaling pathway | 49/1197 | 210/8465 | 2.03e-04 | 1.78e-03 | 1.30e-03 | 49 |
hsa043909 | Endometrium | AEH | Hippo signaling pathway | 38/1197 | 157/8465 | 4.79e-04 | 3.38e-03 | 2.47e-03 | 38 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
ID1 | KER | Skin | ADJ | ID2,ID3,JUNB, etc. | 1.65e-01 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ID1 | SNV | Missense_Mutation | novel | c.283N>T | p.Leu95Phe | p.L95F | P41134 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ID1 | SNV | Missense_Mutation | novel | c.69N>C | p.Lys23Asn | p.K23N | P41134 | protein_coding | deleterious(0.01) | benign(0.444) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ID1 | SNV | Missense_Mutation | rs756315343 | c.350C>T | p.Thr117Ile | p.T117I | P41134 | protein_coding | tolerated(0.21) | benign(0.03) | TCGA-A5-A0GH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ID1 | SNV | Missense_Mutation | c.391A>G | p.Thr131Ala | p.T131A | P41134 | protein_coding | tolerated(0.46) | benign(0.094) | TCGA-B5-A0K9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ID1 | SNV | Missense_Mutation | c.313N>T | p.Leu105Phe | p.L105F | P41134 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A17H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ID1 | SNV | Missense_Mutation | novel | c.346N>A | p.Gly116Arg | p.G116R | P41134 | protein_coding | tolerated(0.42) | benign(0.007) | TCGA-SL-A6J9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ID1 | SNV | Missense_Mutation | novel | c.463N>A | p.Arg155Ser | p.R155S | P41134 | protein_coding | deleterious(0) | benign(0.44) | TCGA-DD-AADO-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ID1 | SNV | Missense_Mutation | c.64G>T | p.Gly22Cys | p.G22C | P41134 | protein_coding | tolerated(0.17) | probably_damaging(0.976) | TCGA-69-7978-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ID1 | SNV | Missense_Mutation | rs758048335 | c.103N>G | p.Leu35Val | p.L35V | P41134 | protein_coding | tolerated(0.09) | probably_damaging(0.991) | TCGA-34-8454-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ID1 | SNV | Missense_Mutation | c.338N>T | p.Ser113Phe | p.S113F | P41134 | protein_coding | deleterious(0) | benign(0.251) | TCGA-BR-7959-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | etoposide | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |